MCL1 and hematologic disorder: In hematological malignancies several compounds have already been demonstrated to have the ability to sensitize cancer cells to ABT-737-induced cell death either through Mcl-1 down-regulation or up-regulation of the endogenous Mcl-1 inhibitor Noxa [37-39].